Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.52% | 7.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.52% | 7.98% | |||
| Cost of Revenue | 3.05% | -4.03% | |||
| Gross Profit | -51.72% | 27.59% | |||
| SG&A Expenses | 6.47% | -0.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.79% | -2.22% | |||
| Operating Income | -218.48% | 44.66% | |||
| Income Before Tax | -154.76% | 36.56% | |||
| Income Tax Expenses | 19.23% | -51.69% | |||
| Earnings from Continuing Operations | -153.69% | 36.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -153.69% | 36.72% | |||
| EBIT | -218.48% | 44.66% | |||
| EBITDA | -222.28% | 45.08% | |||
| EPS Basic | -151.83% | 36.87% | |||
| Normalized Basic EPS | -152.93% | 36.71% | |||
| EPS Diluted | -151.83% | 36.87% | |||
| Normalized Diluted EPS | -152.93% | 36.71% | |||
| Average Basic Shares Outstanding | 0.75% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.75% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||